Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 11:35:50 2024-07-11 am EDT			After market 03:59:59 pm
9.33 ^EUR	-1.79%		9.225	-1.13%

10:05am	Deutsche Bank downgrades Evotec to 'Hold' - annual targets at risk	DP
09:13am	EVOTEC : Deutsche Bank is less optimistic	ZD

NVR: Correction of a release from 11/07/2024, 14:16 CET/CEST - Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

July 11, 2024 at 10:13 am EDT

EQS Total Voting Rights Announcement: Evotec SE
Correction of a release from 11/07/2024, 14:16 CET/CEST - Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

11.07.2024 / 16:11 CET/CEST
Total Voting Rights Announcement transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Correction of a publication dated 11.07.2024

1. Details of issuer

Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany

2. Type of capital measure or other measure

	Type of capital measure or other measure	Date of status / date of effect
X	Conditional capital increase (Sec. 41 para. 2 WpHG)	28.02.2024
	Other (capital) measure (Sec. 41 para. 1 WpHG)

3. New total number of voting rights:

177553385
number of multiple voting rights thereof: 0

11.07.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	Evotec SE
	Manfred Eigen Campus / Essener Bogen 7
	22419 Hamburg
	Germany
Internet:	www.evotec.com


End of News	EQS News Service

1944643 11.07.2024 CET/CEST

Latest news about Evotec SE

Deutsche Bank downgrades Evotec to 'Hold' - annual targets at risk	04:05am	DP
EVOTEC : Deutsche Bank is less optimistic	03:13am	ZD
Pfizer: collaboration agreement with Evotec in France	Jul. 10	CF
Sector Update: Health Care Stocks Steady Premarket Wednesday	Jul. 10	MT
Evotec, Pfizer Enter Research Collaboration on Metabolic, Infectious Diseases	Jul. 10	MT
Evotec, Pfizer Team Up for Early Drug Discovery for Metabolic, infectious Diseases	Jul. 10	MT
Evotec with new recovery attempt - cooperation with Pfizer	Jul. 10	DP
Evotec and Pfizer Collaborate to Advance Drug Discovery in France	Jul. 10	CI
EVOTEC : Deutsche Bank reiterates its Buy rating	Jul. 09	ZD
EVOTEC : Buy rating from RBC	Jul. 08	ZD
Sandoz collaboration extension helps Evotec back to May high	Jul. 08	DP
Evotec's Biologics Segment Expands Sandoz Partnership	Jul. 08	MT
EVOTEC : RBC reiterates its Buy rating	Jul. 03	ZD
Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board	Jun. 30	CI
German Stocks Rise for Second Session	Jun. 28	DJ
German Stocks Reverse Two-Session Losing Streak	Jun. 27	DJ
Sector Update: Health Care Stocks Advance Pre-Bell Tuesday	Jun. 25	MT
Evotec Gets $39 Million Contract With U.S. Defense Department	Jun. 25	DJ
Evotec Unit Bags Contract to Develop Accelerated Antibody Manufacturing Platform for US Government	Jun. 25	MT
Evotec Subsidiary Gets Multi-Year US Defense Department Contract for Up to $39 Million	Jun. 25	MT
Evotec receives additional contract from US Department of Defense	Jun. 25	DP
Dpa-AFX Overview: COMPANIES from 20/06/2024 - 15:15	Jun. 20	DP
Evotec In Talks With Advisers Amid Takeover Worries	Jun. 20	MT
European shares advance on tech, real estate boost; Swiss stocks shine	Jun. 20	RE
Takeover fantasy drives Evotec recovery	Jun. 20	DP

Chart Evotec SE

Duration

Period

More charts

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Sector

Biotechnology & Medical Research

Calendar

2024-08-13 - Q2 2024 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , MDAX

More about the company

Income Statement Evolution

More financial data

Ratings for Evotec SE

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.33 EUR

Average target price

20.72 EUR

Spread / Average Target

+122.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EVOTEC SE	-56.16%	1.82B
MODERNA, INC.	+23.50%	45.01B
LONZA GROUP AG	+47.19%	40.96B
IQVIA HOLDINGS INC.	-5.16%	38.62B
ALNYLAM PHARMACEUTICALS, INC.	+36.37%	32.6B
CELLTRION, INC.	-7.79%	27.49B
ICON PUBLIC LIMITED COMPANY	+18.06%	27.17B
UNITED THERAPEUTICS CORPORATION	+47.29%	14.61B
MEDPACE HOLDINGS, INC.	+41.91%	12.95B
BIO-TECHNE CORPORATION	-1.02%	11.36B

Other Biotechnology & Medical Research